業務
貨幣單位:EUR
2023/FY
名稱營收比例
Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to1,887.3萬36.36%
Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to1,580萬30.44%
Monalizumab agreement - AstraZeneca949.9萬18.30%
Takeda agreement 2023455.3萬8.77%
Sanofi agreement 2016200萬3.85%
Invoicing of research and development costs (IPH5201)116.5萬2.24%
Others1.1萬0.02%
查看全部
地區
貨幣單位:EUR
2023/FY
名稱營收比例
法國5,190.1萬100.00%
